Immune Mechanisms in Liver Disease Pathogenesis

The liver is both a metabolic hub and an immunological organ, housing a complex network of innate and adaptive immune cells that guard against pathogens yet can drive chronic injury when dysregulated. Resident macrophages (Kupffer cells) sense danger signals and recruit monocytes, neutrophils and lymphocytes through chemokine cascades. Innate lymphoid cells and natural killer cell subsets contribute to early inflammation and fibrogenesis, while hepatic stellate cells respond to immune-derived cytokines by depositing extracellular matrix. Adaptive T cell populations—including Th1, Th2, Th17, regulatory T cells (Tregs) and cytotoxic CD8+ T cells—balance pro-inflammatory and anti-inflammatory programmes. Cytokines such as interleukin-17, IL-22, IL-6 and transforming growth factor-β orchestrate hepatocyte survival, fibrotic remodelling and extracellular matrix turnover. Gut–liver immune crosstalk further shapes disease evolution through microbial metabolites and barrier integrity. Together, these mechanisms determine whether fatty liver, steatohepatitis or viral hepatitis progresses to cirrhosis and hepatocellular carcinoma. Understanding these pathways is vital to global health, guiding precision immunotherapies that aim to resolve inflammation, limit fibrosis and restore liver function.

Research from Nature Portfolio

Innovative short-acting bispecific biologics targeting interleukin-22 receptors on liver and pancreatic cells have demonstrated potent efficacy in preclinical models of metabolic dysfunction-associated steatohepatitis (MASH). At tenfold lower doses than native IL-22, these constructs restore glycaemic control, suppress hepatic steatosis, reduce inflammation and attenuate fibrogenesis without off-target epithelial proliferation, highlighting a targeted cytokine-based strategy for MASH treatment.

Immune Mechanisms in Liver Disease Pathogenesis publication trend

The graph below shows the total number of articles in immune mechanisms in liver disease pathogenesis across all publications each year (not limited to Nature Index journals).

Technical terms

Interleukin-22 (IL-22): A cytokine produced by immune cells that promotes hepatocyte survival, regeneration and anti-inflammatory responses.

Bispecific biologic: A fusion protein engineered to engage two distinct targets or receptors, enhancing tissue specificity and therapeutic index.

Regulatory T cell (Treg): A subset of CD4+ lymphocytes that suppresses excessive immune activation and maintains hepatic immune tolerance.

Nr4a family: Orphan nuclear receptors that regulate gene expression in T cells, influencing their proliferation, differentiation and impact on fibrosis.

Metabolic dysfunction–associated steatohepatitis (MASH): A form of chronic liver disease marked by fat accumulation, inflammation and fibrotic remodelling linked to metabolic syndrome.

References

1. Decoding the role of immune T cells: A new territory for improvement of metabolic‐associated fatty liver disease. iMeta (2023).
2. Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis. Nature Communications (2024).
3. The Nr4a family regulates intrahepatic Treg proliferation and liver fibrosis in MASLD models. Journal of Clinical Investigation (2024).